{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-280679","form_type":"8-K","ticker":null,"cik":"0001069308","company_name":"Acer Therapeutics Inc.","filed_at":"2023-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.113377+00:00","generated_at":"2026-06-07T23:10:25.211486+00:00","sec_items":["2.01","3.03","3.01","5.01","5.02","5.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Acer Therapeutics acquired by Zevra in all-stock merger; shareholders receive 0.1210 ZVRA shares + CVR","bullets":["Merger completed on Nov 17, 2023; Acer becomes wholly-owned subsidiary of Zevra.","Each ACER share converted into 0.1210 Zevra shares and one contingent value right (CVR).","All Acer directors and executive officers (CEO Chris Schelling, CFO Harry Palmin) resigned; R. LaDuane Clifton and Joshua Schafer appointed directors.","Acer's common stock now trades on OTC Pink; Nasdaq delisting expected via Form 25-NSE on Nov 20."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-280679","json":"https://secwatch.observer/filing/0001193125-23-280679.json","markdown":"https://secwatch.observer/filing/0001193125-23-280679.md","text":"https://secwatch.observer/filing/0001193125-23-280679.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/d608859d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T23:10:25.211486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"066ac4b1d5","claim":"Harry S. Palmin departed as Chief Financial Officer at Acer Therapeutics Inc..","evidence_excerpt":"On November 17, 2023, each of Chris Schelling, Acer’s President and Chief Executive Officer, and Harry S. Palmin, Acer’s Chief Financial Officer, ceased to be an executive officer of Acer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"219d4d20a3","claim":"John M. Dunn resigned as Director at Acer Therapeutics Inc..","evidence_excerpt":"Stephen J. Aselage, Jason Amello, John M. Dunn, Michelle Griffin and Chris Schelling each resigned and ceased serving as directors of Acer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"323bec2dee","claim":"Jason Amello resigned as Director at Acer Therapeutics Inc..","evidence_excerpt":"Stephen J. Aselage, Jason Amello, John M. Dunn, Michelle Griffin and Chris Schelling each resigned and ceased serving as directors of Acer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"67e52005ef","claim":"Stephen J. Aselage resigned as Director at Acer Therapeutics Inc..","evidence_excerpt":"Stephen J. Aselage, Jason Amello, John M. Dunn, Michelle Griffin and Chris Schelling each resigned and ceased serving as directors of Acer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b51e3b18f4","claim":"Chris Schelling departed as President and Chief Executive Officer at Acer Therapeutics Inc..","evidence_excerpt":"On November 17, 2023, each of Chris Schelling, Acer’s President and Chief Executive Officer, and Harry S. Palmin, Acer’s Chief Financial Officer, ceased to be an executive officer of Acer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"d488764fee","claim":"Michelle Griffin resigned as Director at Acer Therapeutics Inc..","evidence_excerpt":"Stephen J. Aselage, Jason Amello, John M. Dunn, Michelle Griffin and Chris Schelling each resigned and ceased serving as directors of Acer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f0e8b1fbda","claim":"Joshua Schafer was appointed as Director at Acer Therapeutics Inc..","evidence_excerpt":"On November 17, 2023, R. LaDuane Clifton and Joshua Schafer became the directors of the surviving corporation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f1f0ca0501","claim":"R. LaDuane Clifton was appointed as Director at Acer Therapeutics Inc..","evidence_excerpt":"On November 17, 2023, R. LaDuane Clifton and Joshua Schafer became the directors of the surviving corporation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ff066be632","claim":"Chris Schelling resigned as Director at Acer Therapeutics Inc..","evidence_excerpt":"Stephen J. Aselage, Jason Amello, John M. Dunn, Michelle Griffin and Chris Schelling each resigned and ceased serving as directors of Acer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"079482d189f367bbaf110451a7cca1965467fbb7","claim":"Acer Therapeutics Inc.: Bylaws amended and restated to match Merger Sub's bylaws.","evidence_excerpt":"Acer’s bylaws were amended and restated to read in their entirety as the bylaws of Merger Sub in effect immediately prior to the Effective Time","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"37db88b0114d7a45c73a12a7e44d035810cb5b48","claim":"Acer Therapeutics Inc.: Certificate of incorporation amended and restated to match Merger Sub's certificate.","evidence_excerpt":"Acer’s certificate of incorporation was amended and restated to read in its entirety (other than the name of Acer) as the certificate of incorporation of Merger Sub in effect immediately prior to the Effective Time","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"bc21c44077ff875d0eb3013e8df1ce2153315e68","claim":"Acer Therapeutics Inc. underwent a change of control involving Zevra Therapeutics, Inc. (closed 2023-11-17).","evidence_excerpt":"On November 17, 2023 (the “ Closing Date ”), the Merger was completed pursuant to the terms and conditions of the Merger Agreement.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069308/000119312523280679/0001193125-23-280679-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Zevra Therapeutics, Inc."},{"label":"Closing","value":"2023-11-17"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}